Centessa Sleep Disorder Drug Sales Could Eventually Top $2.5B -- Market Talk

Dow Jones03-25

1351 ET - As Centessa Pharmaceuticals reports results and predicts a "data-rich" year, TD Cowen is optimistic about its ORX750 drug for sleep disorders. "Given 750's competitive wake-promoting efficacy and clean tolerability, we are optimistic for the Phase IIa results this year," the firm says. It anticipates a large overall market for OXR2 agonists, and says on-target adverse events for ORX750 "appear to be lower than competitors at same stage of development." TD Cowen assumes a 2028 market introduction and believes sales could eventually top $2.5 billion. Centessa says cash and equivalents totaled $482.2 million at Dec. 31, which would fund operations into mid-2027. Centessa previously said it will present data from a Phase 1 ORX750 trial during an American Academy of Neurology meeting to be held April 5 to April 9. Shares rise 4.9%. (josh.beckerman@wsj.com)

(END) Dow Jones Newswires

March 24, 2025 13:51 ET (17:51 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2522703043?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-25 01:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522703043","market":"hk","top_or_hot":-1,"title":"Centessa Sleep Disorder Drug Sales Could Eventually Top $2.5B -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1351 ET - As Centessa Pharmaceuticals reports results and predicts a \"data-rich\" year, TD Cowen is optimistic about its ORX750 drug for sleep disorders. \"Given 750's competitive wake-promoting efficacy and clean tolerability, we are optimistic for the Phase IIa results this year,\" the firm says. It anticipates a large overall market for OXR2 agonists, and says on-target adverse events for ORX750 \"appear to be lower than competitors at same stage of development.\" TD Cowen assumes a 2028 market introduction and believes sales could eventually top $2.5 billion. Centessa says cash and equivalents totaled $482.2 million at Dec. 31, which would fund operations into mid-2027. Centessa previously said it will present data from a Phase 1 ORX750 trial during an American Academy of Neurology meeting to be held April 5 to April 9. Shares rise 4.9%. (josh.beckerman@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 24, 2025 13:51 ET (17:51 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Centessa Sleep Disorder Drug Sales Could Eventually Top $2.5B -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCentessa Sleep Disorder Drug Sales Could Eventually Top $2.5B -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-25 01:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1351 ET - As Centessa Pharmaceuticals reports results and predicts a \"data-rich\" year, TD Cowen is optimistic about its ORX750 drug for sleep disorders. \"Given 750's competitive wake-promoting efficacy and clean tolerability, we are optimistic for the Phase IIa results this year,\" the firm says. It anticipates a large overall market for OXR2 agonists, and says on-target adverse events for ORX750 \"appear to be lower than competitors at same stage of development.\" TD Cowen assumes a 2028 market introduction and believes sales could eventually top $2.5 billion. Centessa says cash and equivalents totaled $482.2 million at Dec. 31, which would fund operations into mid-2027. Centessa previously said it will present data from a Phase 1 ORX750 trial during an American Academy of Neurology meeting to be held April 5 to April 9. Shares rise 4.9%. (josh.beckerman@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 24, 2025 13:51 ET (17:51 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CNTA","symbol_name":"Centessa Pharmaceuticals plc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2522703043","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522703043","pubTimestamp":1742838660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1351 ET - As Centessa Pharmaceuticals reports results and predicts a \"data-rich\" year, TD Cowen is optimistic about its ORX750 drug for sleep disorders. \"Given 750's competitive wake-promoting efficacy and clean tolerability, we are optimistic for the Phase IIa results this year,\" the firm says. It anticipates a large overall market for OXR2 agonists, and says on-target adverse events for ORX750 \"appear to be lower than competitors at same stage of development.\" TD Cowen assumes a 2028 market introduction and believes sales could eventually top $2.5 billion. Centessa says cash and equivalents totaled $482.2 million at Dec. 31, which would fund operations into mid-2027. Centessa previously said it will present data from a Phase 1 ORX750 trial during an American Academy of Neurology meeting to be held April 5 to April 9. Shares rise 4.9%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CNTA":"Centessa Pharmaceuticals plc"},"translate_title":"Centessa睡眠障碍药物销售额最终可能突破$2.5 B——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNTA":0.9},"content_text":"1351 ET - As Centessa Pharmaceuticals reports results and predicts a \"data-rich\" year, TD Cowen is optimistic about its ORX750 drug for sleep disorders. \"Given 750's competitive wake-promoting efficacy and clean tolerability, we are optimistic for the Phase IIa results this year,\" the firm says. It anticipates a large overall market for OXR2 agonists, and says on-target adverse events for ORX750 \"appear to be lower than competitors at same stage of development.\" TD Cowen assumes a 2028 market introduction and believes sales could eventually top $2.5 billion. Centessa says cash and equivalents totaled $482.2 million at Dec. 31, which would fund operations into mid-2027. Centessa previously said it will present data from a Phase 1 ORX750 trial during an American Academy of Neurology meeting to be held April 5 to April 9. Shares rise 4.9%. (josh.beckerman@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2025 13:51 ET (17:51 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2522703043","isCrawlerRequest":true}